MeiraGTx Holdings (MGTX) Gross Margin (2024 - 2025)
MeiraGTx Holdings (MGTX) reported Gross Margin of 99.37% for Q4 2025, up 5456.0% on a YoY basis from 1.79% in Q4 2024, and up 320.01% quarter-over-quarter from 23.66% in Q3 2025.
MeiraGTx Holdings (MGTX) Gross Margin (2024 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Gross Margin for 2 years, with the latest figure at 99.37% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 5456.0% year-over-year to 99.37%; the trailing twelve-month figure through Dec 2025 stood at 84.86% (changed N/A YoY), and the FY2025 full-year result was 94.05%, up 6554.0% from the prior year.
- Gross Margin for Q4 2025 stood at 99.37%, up from 23.66% in the prior quarter.
- The five-year high for Gross Margin was 99.37% in Q4 2025, with the low at 9.85% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 99.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 99.37% |
| Sep 30, 2025 | 23.66% |
| Jun 30, 2025 | 27.50% |
| Dec 31, 2024 | 44.81% |
| Sep 30, 2024 | -9.85% |